Harmony Hybrid

Making complex hybrid procedures safer

About Us

We are a privately owned, Dublin based business committed to designing and developing a range of devices for hybrid procedures

Discover Hybrid Harmony


Our mission is to develop less invasive devices to assist in complex congenital and structural heart procedures – in infants and adults. We are doing this by working with leaders in coronary intervention and surgery to design practical solutions that make procedures safer and less traumatic – promoting faster and healthier long-term healing.

Leadership Team

Brian Bailey – CEO

Brian Bailey has over 25 years experience in Cardiology device distribution and sales in Ireland. Brian is founder and managing Director of Medilex Limited. Medilex are a distribution company for specialised cardiology devices which was formed in 2007. Prior to that Brian was a Director of Bailey Medical Limited which was sold to Cardiac Services in 2004. Brian has worked with many the major international medtech manufactures.

Prof. Kevin Walsh – Clinical Director

Professor Kevin Walsh is a Cardiology Consultant specialising in congenital heart disease, both adult and paediatric. He is Clinical lead for the National Adult Congenital Heart Service at the Mater Misericordia University Hospital, Dublin. His major interest is in interventional cardiology for both congenital and structural heart disease. He has special interest in device occlusion of septal defects with pioneering work on many of the current devices in clinical use today. He performed the First In Man implantation of Amplatzer Cardiac Plug for atrial fibrillation at the Beacon Hospital in 2008, the first licensed Melody pulmonic valve implantation in Europe in 2006 and first percutaneous reversed Potts shunt for Pulmonary hypertension in the British Isles in 2018.

Prof. Damien Kenny – Clinical Director

Prof. Damien Kenny is a Consultant Congenital Cardiologist in Our Lady’s Children’s Hospital Crumlin, and Mater Hospital, Dublin, Ireland. In late 2017, he was appointed as a RCSI Clinical Associate Professor. He has previously held an Honorary Consultant post in Paediatric Cardiac Transplantation and Heart Failure, Great Ormond Street Hospital, UK. In the USA, at Rush University Medical Center, he was Assistant Professor of Pediatrics and Internal Medicine and later worked as the Director of the Cardiac Catheterisation Hybrid Suite.

He is a Director of the PICS~AICS meeting, the largest international meeting dedicated solely to international therapies for children and adults with congenital heart disease.  He was part of the Scientific Advisory Committee for the 2017 World Congress of Pediatric Cardiology and Cardiac Surgery in Barcelona and will continue the role for the World Congress in Washington in 2021. He also co-founded CHIMS, an organisation committed to centralising and re-distributing donated catheterisation equipment to developing countries He is involved in research in Ireland and abroad, having published over 120 peer reviewed articles and co-authored 20 chapters in International textbooks. His research areas of interest include Interventional Therapies for Congenital Heart Disease; Pediatric and Congenital Heart Failure and Adult Congenital Heart Disease.

Jonathan Akehurst – Commercial Director

Jonathan Akehurst Commercial Director 30+ years in Business Development & Marketing – in pharma and medical devices. He is the former Commercial Head of ClearStream Technologies PLC Wexford where he led the business into 40+ international markets. He is the former CEO of Cappella Medical Devices Galway – here he led a team developing devices from R&D through to full commercialisation & export

What is a Hybrid Procedure?

Management of complex congenital heart defects in the neonatal period has traditionally been surgical. In recent years, a hybrid approach has been developed, where surgeons and interventional cardiologists combine their expertise in correcting or palliating complex heart defects in neonates, infants and children; that cannot be adequately addressed by surgery or interventional catheterisation alone. These procedures require specific functional devices, designed to optimise safety.

Our Technology

Hybrid SaferSheath TM

-Designed for hybrid procedures

-‘Anchor & Lock’ TM


-Range of French sizes

Please note this device is under development and is not for sale or use


Voted ‘Best Innovation’ at PICS Congress September 2018

$25k prize money invested in patent development

Worldwide patent published March 2020

Contact Us

4 + 3 =

Hybrid Harmony